Seattle Genetics Announces Multiple Presentations at Upcoming American Association for Cancer Research Annual Meeting.BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN SGEN Signal/System Generator ) today announced that fifteen abstracts associated with the company's ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. technology, antibody-based therapeutics and collaborator programs will be presented at the 2007 Annual Meeting of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ) to be held April 14-18, 2007, at the Los Angeles Convention Center The Los Angeles Convention Center (abbreviated LACC) is a convention center in downtown Los Angeles. The LACC hosts annual events such as the Greater Los Angeles Auto Show, and was best known to video games fans as host to E3 until its cessation in 2006. , Los Angeles, CA. In addition, Peter D. Senter, Ph.D., Vice President, Chemistry at Seattle Genetics will present during an educational session entitled "Novel Approaches to Drug Delivery in Cancer" on April 14, 2007 from 8:00 a.m. to 10:00 a.m. Dr. Senter's presentation is titled "Potent Immunoconjugates for Cancer Therapy." Presentation details: ADC Technology "Determining relative tubulin tubulin /tu·bu·lin/ (too´bu-lin) the constituent protein of microtubules. tu·bu·lin n. A globular protein that is the structural constituent of microtubules. binding affinity in an auristatin library" Poster Session Sunday, April 15, 2007; 8:00am - 12:00pm Pacific Time (PT) Abstract #658 "Glypican-3 as a novel target for an antibody drug conjugate" Poster Session Sunday, April 15, 2007; 8:00am - 12:00pm PT Abstract #656 "Effects of linker chemistry on tumor targeting by anti-CD70 antibody-drug conjugates" Poster Session Sunday, April 15, 2007; 1:00pm - 5:00pm PT Abstract #916 "CD133/prominin-1 is a novel antibody therapeutic target in pancreatic, gastric and hepatocellular cancers" Poster Session Sunday, April 15, 2007; 1:00pm - 5:00pm PT Abstract #1332 "Efficacy of antibody targeted auristatin chemotherapy in a rat intracerebral in·tra·cer·e·bral adj. Existing within the cerebrum. tumor model" Poster Session Monday, April 16, 2007; 1:00pm - 5:00pm PT Abstract #3332 "Effective tumor targeting by auristatin antibody-drug conjugates" Poster Session Tuesday, April 17, 2007; 8:00am - 12:00pm PT Abstract #4088 "An antibody-FRET conjugate that sheds light on intracellular antibody-drug conjugate activation" Poster Session Tuesday, April 17, 2007; 8:00am - 12:00pm PT Abstract #4086 "Novel auristatins with improved therapeutic indices for monoclonal antibody-mediated delivery" Poster Session Tuesday, April 17, 2007; 1:00pm - 5:00pm PT Abstract #4793 SGN-33 Program "SGN-33 (lintuzumab), a humanized anti-CD33 antibody, modulates the activity of CD33-positive tumor-associated macrophages Macrophages White blood cells whose job is to destroy invading microorganisms. Listeria monocytogenes avoids being killed and can multiply within the macrophage. " Poster Session Tuesday, April 17, 2007; 8:00am - 12:00pm PT Abstract #4111 SGN-30 Program "Characterization of Fc-mediated effector effector /ef·fec·tor/ (e-fek´ter) 1. an agent that mediates a specific effect. 2. an organ that produces an effect in response to nerve stimulation. functions of SGN-30 in vitro and in vivo" Poster Session Sunday, April 15, 2007; 8:00am - 12:00pm PT Abstract #661 Collaborator Presentations "Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics" (Genentech) Poster Session Sunday, April 15, 2007; 1:00pm - 5:00pm PT Abstract #1551 "Proteomic analysis of colorectal tumor cells identifies CD133/prominin-1, a cancer stem cell Cancer stem cell hypothesis states that tumors arise from cells termed cancer stem cells that have properties of adult stem cells, particularly the abilities to self-renew and differentiate into multiple cell types, and that these cells persist in tumors as a distinct population marker, as a monoclonal antibody therapeutic candidate" (Celera) Poster Session Sunday, April 15, 2007; 1:00pm - 5:00pm PT Abstract #1324 "Armed antibodies targeted to STEAP STEAP Six Transmembrane Epithelial Antigen of the Prostate STEAP Shore Test Equipment Allowance Program STEAP Summer Transitional Employment and Assessment Program STeaP Super TEA People (vodcast) 1 inhibit growth of human prostate xenografts in vivo" (Genentech) Poster Session Tuesday, April 17, 2007; 1:00pm - 5:00pm PT Abstract #4468 "Forced resistance to PSMA PSMA Public Sector Mapping Agencies (Australia) PSMA Prostate-Specific Membrane Antigen PSMA Power Sources Manufacturers Association PSMA Pakistan Sugar Mills Association PSMA Professional Services Management Association ADC, a novel targeted therapy for prostate cancer, does not confer cross-resistance to docetaxel or other cytotoxic agents" (Progenics) Poster Session Tuesday, April 17, 2007; 8:00am - 12:00pm PT Abstract #4102 "A human monoclonal antibody-drug conjugate against EphA2 inhibits tumor growth in vivo through the induction of apoptosis" (MedImmune) Oral Presentation Wednesday, April 18, 2007; 10:40am - 10:55am PT; Room 306 A-B A-B Air-Britain (UK-based aviation historical society) A-B Research Centre Applied Biocatalysis (Graz, Austria) Abstract #5744 About Seattle Genetics Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including lymphoma, multiple myeloma, leukemia and solid tumors. The company has an exclusive worldwide license agreement with Genentech to develop and commercialize SGN-40. Seattle Genetics also has three proprietary programs in ongoing clinical trials: SGN-33, SGN-35 and SGN-30. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune, as well as an ADC co-development agreement with Agensys. More information can be found at www.seattlegenetics.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion